UK British Business Bank makes GBP 50m cornerstone commitment to Epidarex Capital Fund IV

Mechanism

The British Business Bank (BBB) committed GBP 50 million as a cornerstone investor in Epidarex Capital's fourth flagship fund, Epidarex Capital IV, LP. Epidarex is a transatlantic early-stage life sciences investor headquartered in Edinburgh with an office in Bethesda, MD, providing Seed and Series A funding to therapeutics and medical-device companies addressing oncology, cardiometabolic, autoimmune and neurological disease, often partnering with medical universities and research institutions on both sides of the Atlantic. Fund IV announced a first close of USD 145 million on 27 January 2026, with the BBB joined by the Strathclyde Pension Fund, the Scottish National Investment Bank, and leading family offices and corporate investors; the fund expects to back roughly 15 companies.

This is BBB's second cornerstone commitment to Epidarex, following a GBP 50 million stake in Epidarex Capital III UK, LP (part of a GBP 102 million fund) in 2020 — the same cornerstone-investor, fund-of-funds model BBB uses across its deeptech and life-sciences venture book (see IQ Capital Fund V, WestBridge III).

Downstream implications

• Fund-level commitment (GBP 50m disclosed, quant) rather than a

single-company stake; severity set at 1, consistent with prior BBB fund-commitment filings of similar scale.

• Reinforces UK life-sciences/biotech venture capital as a recurring

BBB cornerstone-allocation target, alongside deeptech/AI-compute (IQ Capital) and regional-growth (WestBridge) fund commitments.

• GTA logs the deal as trade-distorting state financial support (fund

commitment, classified "Red"); no export- or trade-control dimension is present.

Open questions

• Which portfolio companies Epidarex Capital IV backs from its

roughly 15-company target, and whether any attract later investment-screening or foreign-takeover scrutiny.

• Whether BBB continues stacking life-sciences fund commitments at

this cadence through 2026.